Literature DB >> 1359801

The progression of untreated HIV-1 infection prior to AIDS.

D R Hoover1, A Saah, H Bacellar, R Murphy, B Visscher, S Metz, R Anderson, R A Kaslow.   

Abstract

Using a case-control study of untreated men, we investigated the physical, mental, and economic effects of human immunodeficiency virus (HIV-1) infection prior to the diagnosis of acquired immunodeficiency syndrome (AIDS). Beginning 2 to 2.5 years prior to AIDS, case subjects reported more of 12 HIV-1 related symptoms and during the year prior to AIDS, at least 30.6 extra days of these symptoms than did control subjects. Within the 6 months preceding AIDS, case subjects' unemployment rose to 9% (P < or = .05) and depression to 34.2% (P < or = .001). At 6 to 12 months and within 6 months before AIDS, 17.1% and 31.5%, respectively, were anemic, while 37.7% and 64.7% had CD4+ counts less than 200 x 10(6)/L. Diagnosing AIDS at CD4+ counts less than 200 x 10(6)/L could significantly reduce pre-AIDS morbidity. Other implications of these findings are discussed.

Entities:  

Mesh:

Year:  1992        PMID: 1359801      PMCID: PMC1694603          DOI: 10.2105/ajph.82.11.1538

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  9 in total

1.  Effect of new AIDS case definition on numbers of cases among homosexual and bisexual men in San Francisco.

Authors:  H W Sheppard; W Winkelstein; D Osmond; A R Moss
Journal:  JAMA       Date:  1991 Oct 23-30       Impact factor: 56.272

2.  Effect of CD4+ cell count measurement variability on staging HIV-1 infection.

Authors:  D R Hoover; N M Graham; B Chen; J M Taylor; J Phair; S Y Zhou; A Muñoz
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

3.  The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants.

Authors:  R A Kaslow; D G Ostrow; R Detels; J P Phair; B F Polk; C R Rinaldo
Journal:  Am J Epidemiol       Date:  1987-08       Impact factor: 4.897

4.  The impact of HIV-related illness on employment.

Authors:  E H Yelin; R M Greenblatt; H Hollander; J R McMaster
Journal:  Am J Public Health       Date:  1991-01       Impact factor: 9.308

5.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  D D Richman; M A Fischl; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; M S Hirsch
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

6.  Infection with the human immunodeficiency virus: clinical manifestations and their relationship to immune deficiency. A report from the Multicenter AIDS Cohort Study.

Authors:  R A Kaslow; J P Phair; H B Friedman; D Lyter; R E Solomon; J Dudley; B F Polk; W Blackwelder
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

7.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Authors:  M A Fischl; D D Richman; N Hansen; A C Collier; J T Carey; M F Para; W D Hardy; R Dolin; W G Powderly; J D Allan
Journal:  Ann Intern Med       Date:  1990-05-15       Impact factor: 25.391

8.  Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort.

Authors:  A R Moss; P Bacchetti; D Osmond; W Krampf; R E Chaisson; D Stites; J Wilber; J P Allain; J Carlson
Journal:  Br Med J (Clin Res Ed)       Date:  1988-03-12

9.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

  9 in total
  7 in total

1.  Decreased depression up to one year following CBSM+ intervention in depressed women with AIDS: the smart/EST women's project.

Authors:  Arthur Laperriere; Gail H Ironson; Michael H Antoni; Heidi Pomm; Deborah Jones; Mary Ishii; David Lydston; Peter Lawrence; Alison Grossman; Elizabeth Brondolo; Andrea Cassells; Jonathan N Tobin; Neil Schneiderman; Stephen M Weiss
Journal:  J Health Psychol       Date:  2005-03

2.  Depressive symptoms over the course of HIV infection before AIDS.

Authors:  C G Lyketsos; D R Hoover; M Guccione; M A Dew; J Wesch; E G Bing; G J Treisman
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1996-06       Impact factor: 4.328

3.  Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid.

Authors:  J G Kahn; B Haile; J Kates; S Chang
Journal:  Am J Public Health       Date:  2001-09       Impact factor: 9.308

4.  Weight loss and body mass index as predictors of HIV disease progression to AIDS in adults. Aquitaine cohort, France, 1985-1997.

Authors:  E Malvy; R Thiébaut; C Marimoutou; F Dabis
Journal:  J Am Coll Nutr       Date:  2001-12       Impact factor: 3.169

5.  Association between major depressive disorder and pro-inflammatory cytokines and acute phase proteins among HIV-1 positive patients in Uganda.

Authors:  Kenneth Musinguzi; Andrew Obuku; Noeline Nakasujja; Harriet Birabwa; Juliet Nakku; Jonathan Levin; Eugene Kinyanda
Journal:  BMC Immunol       Date:  2018-01-03       Impact factor: 3.615

6.  Changes in depressive symptoms and correlates in HIV+ people at An Hoa Clinic in Ho Chi Minh City, Vietnam.

Authors:  Van-Anh N Huynh; Kien G To; Dung Van Do; Quyen G To; Mai T H Nguyen
Journal:  BMC Psychiatry       Date:  2017-01-21       Impact factor: 3.630

7.  Blood haemoglobin measurement as a predictive indicator for the progression of HIV/AIDS in resource-limited setting.

Authors:  Christian Obirikorang; Francis A Yeboah
Journal:  J Biomed Sci       Date:  2009-11-18       Impact factor: 8.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.